Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PIQLF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -84.45 Med: -13.77 Max: -0.35
Current: -1.98
During the past 11 years, the highest EV-to-EBITDA of Proteomics International Laboratories was -0.35. The lowest was -84.45. And the median was -13.77.
PIQLF's EV-to-EBITDA is ranked worse than 100% of 397
companies
in the Biotechnology industry
Industry Median: 12.31
vs PIQLF: -1.98
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Proteomics International Laboratories (OTCPK:PIQLF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Proteomics International Laboratories's PE Ratio (TTM) for today is calculated as:
Proteomics International Laboratories's share price for today is $0.26.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Proteomics International Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.044.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories EV-to-EBITDA Chart
PIQLF vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Proteomics International Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteomics International Laboratories EV-to-EBITDA vs Biotechnology Industry
Proteomics International Laboratories's current Enterprise Value is $15.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Proteomics International Laboratories's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-7.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories (PIQLF) has a EV-to-EBITDA of -2.07 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Proteomics International Laboratories. According to the industry distribution chart, Proteomics International Laboratories ranks #999999 out of 397 companies in the Biotechnology industry.
Is Proteomics International Laboratories' EV-to-EBITDA too high?
Proteomics International Laboratories' current EV-to-EBITDA is -2.07. Based on the distribution chart, Proteomics International Laboratories ranks #999999 out of 397 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Proteomics International Laboratories has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Proteomics International Laboratories' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Proteomics International Laboratories ranks #999999 out of 397 companies for EV-to-EBITDA. This places Proteomics International Laboratories in the lower half of its industry. The industry median EV-to-EBITDA is 12.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.31, based on 397 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Proteomics International Laboratories. For the Biotechnology industry, the median EV-to-EBITDA is 12.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteomics International Laboratories's current EV-to-EBITDA is -2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteomics International Laboratories stock overvalued right now?
Proteomics International Laboratories (PIQLF) has a current EV-to-EBITDA of -2.07. The stock's GF Value™ is $0.64, compared to a current price of $0.26 — trading 59.4% below its estimated fair value. The current EV-to-EBITDA is -2.07. Proteomics International Laboratories' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Proteomics International Laboratories (PIQLF), the current EV-to-EBITDA is -2.07 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Proteomics International Laboratories (PIQLF) Overvalued in 2026?
Based on GuruFocus' analysis, Proteomics International Laboratories stock appears to be undervalued.
The current stock price of $0.26 is trading 59.4% below its estimated GF Value™ of $0.64.
Key valuation signals for PIQLF:
EV-to-EBITDA: -2.07
GF Value™: $0.64 vs. price of $0.26 (59.4% below fair value)
No single metric tells the full story. See the PIQLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Proteomics International Laboratories Business Description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
31GF Score
Get the complete analysis for PIQLF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PIQLF has been successfully added to your 
